Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1873 1
1889 1
1904 1
1917 1
1962 1
1965 1
1967 1
1968 5
1969 4
1970 1
1971 1
1972 2
1973 4
1974 2
1975 6
1976 6
1977 12
1978 5
1979 7
1980 7
1981 5
1982 10
1983 10
1984 9
1985 7
1986 13
1987 14
1988 12
1989 12
1990 12
1991 19
1992 22
1993 19
1994 22
1995 27
1996 15
1997 16
1998 20
1999 20
2000 9
2001 16
2002 23
2003 16
2004 24
2005 11
2006 32
2007 35
2008 31
2009 41
2010 39
2011 44
2012 50
2013 59
2014 78
2015 65
2016 49
2017 35
2018 34
2019 40
2020 46
2021 70
2022 66
2023 62
2024 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,272 results

Results by year

Filters applied: . Clear all
Page 1
Pediatric Flatfoot: Pearls and Pitfalls.
Ford SE, Scannell BP. Ford SE, et al. Foot Ankle Clin. 2017 Sep;22(3):643-656. doi: 10.1016/j.fcl.2017.04.008. Epub 2017 Jun 3. Foot Ankle Clin. 2017. PMID: 28779814 Review.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Overton ET, et al. Among authors: ford s. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9. Lancet. 2021. PMID: 33308425 Clinical Trial.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, Polli JW, Dorey D, Wang Y, Wu S, Van Eygen V, Crauwels H, Ford SL, Baker M, Talarico CL, Clair MS, Jeffrey J, White CT, Vanveggel S, Vandermeulen K, Margolis DA, Aboud M, Spreen WR, van Lunzen J. Cutrell AG, et al. Among authors: ford sl. AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883. AIDS. 2021. PMID: 33730748 Free PMC article.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y, Han K, Van Eygen V, Crauwels H, Ford SL, Latham CL, St Clair M, Polli JW, Vanveggel S, Vandermeulen K, D'Amico R, Garges HP, Zolopa A, Spreen WR, van Wyk J, Cutrell AG. Orkin C, et al. Among authors: ford sl. Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370. Clin Infect Dis. 2023. PMID: 37340869 Free PMC article.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Rizzardini G, et al. Among authors: ford sl. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. J Acquir Immune Defic Syndr. 2020. PMID: 33136751 Free PMC article. Clinical Trial.
Asperger's syndrome - about time to rename it?
Bearer C, Abman SH, Agostoni C, Ballard P, Bliss J, de Boode WP, Canpolat FE, Chalak L, Cilio MR, Dammann O, Davis J, El-Metwally D, Ferriero D, Ford S, Fuentes-Afflick E, Gano D, Giussani D, Gonzalez F, Gunn A, Hogeveen M, Huang AY, Kaplan J, Klebanoff M, Lachman P, Mak R, Malhotra A, Miller S, Mitchell WB, Molloy E, Mulkey SB, Roland D, Sampath V, Sant'Anna G, Schaff P, Singer LT, Stroustrup A, Tingay D, Tiribelli C, Toldi G, Tryggestad J, Valente EM, Wilson-Costello D, Zupancic J. Bearer C, et al. Among authors: ford s. Pediatr Res. 2024 Feb;95(3):582-584. doi: 10.1038/s41390-023-02885-8. Epub 2023 Nov 13. Pediatr Res. 2024. PMID: 37957241 No abstract available.
Gender Dysphoria in the Military.
Ford S, Schnitzlein C. Ford S, et al. Curr Psychiatry Rep. 2017 Nov 7;19(12):102. doi: 10.1007/s11920-017-0845-z. Curr Psychiatry Rep. 2017. PMID: 29110095 Review.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S, Thiagarajah S, Van Solingen-Ristea R, Ford SL, Crauwels H, Patel P, Cutrell A, Smith KY, Vandermeulen K, Birmingham E, St Clair M, Spreen WR, D'Amico R. Orkin C, et al. Among authors: ford sl. Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14. Lancet HIV. 2021. PMID: 34656207 Clinical Trial.
Current management of benign retroperitoneal tumors.
Tirotta F, Napolitano A, Noh S, Schmitz E, Nessim C, Patel D, Sicklick JK, Smith M, Thway K, van der Hage J, Ford SJ, Tseng WW. Tirotta F, et al. Among authors: ford sj. Eur J Surg Oncol. 2023 Jun;49(6):1081-1090. doi: 10.1016/j.ejso.2022.07.006. Epub 2022 Jul 19. Eur J Surg Oncol. 2023. PMID: 35879135 Review.
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, Parra RS, Ford S, Remple VP, Lacerda AP, Anyanwu SI, Mallick M, Garrison A, Regueiro M. Colombel JF, et al. Among authors: ford s. Clin Gastroenterol Hepatol. 2024 Aug;22(8):1668-1677. doi: 10.1016/j.cgh.2024.02.027. Epub 2024 Mar 15. Clin Gastroenterol Hepatol. 2024. PMID: 38492903 Free article. Clinical Trial.
1,272 results